Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition

Area of Science:

• Oncology
• Molecular Diagnostics
• Health Economics

Background:

• Precision medicine and targeted therapies rely on advanced molecular diagnostics.
• Value-based healthcare models influence decisions on diagnostic test adoption and reimbursement.
• The value proposition framework assesses laboratory testing benefits for all stakeholders.

Purpose of the Study:

• To apply the value proposition concept to noninvasive plasma epidermal growth factor receptor (EGFR) mutation testing in advanced or metastatic non-small cell lung cancer (NSCLC).
• To evaluate the clinical validity, economic implications, and limitations of plasma EGFR mutation testing for guiding EGFR tyrosine kinase inhibitor (TKI) treatment.

Main Methods:

• Literature review of published evidence on plasma EGFR mutation testing.
• Application of the value proposition framework to assess benefits across the patient care pathway.
• Evaluation of clinical utility, economic impact, and practical limitations.

Main Results:

• Plasma EGFR mutation testing is crucial for predicting TKI eligibility, enabling real-time treatment monitoring, and tracking resistance.
• This noninvasive approach provides clinical benefits by guiding treatment decisions and reducing the need for invasive tissue biopsies.
• Economic benefits are realized across the healthcare system, particularly when tissue biopsy is inadequate or not feasible.

Conclusions:

• Plasma EGFR mutation testing is an essential tool in precision oncology for non-small cell lung cancer management.
• The value proposition of this diagnostic approach is supported by clinical efficacy and economic advantages.
• Its use is particularly beneficial in scenarios where tissue biopsy is challenging, optimizing patient care and resource utilization.